Key result
Rostafuroxin reduces ouabain-induced heart rate variability and sinus arrest by normalizing cardiomyocyte Na+ overload.
Why the study?
Cardiac glycoside use is limited by a narrow therapeutic window where overdosing causes arrhythmias from electrolyte disturbances, prompting testing of whether rostafuroxin prevents these derangements.
Does rostafuroxin prevent ouabain-induced electrophysiological derangements and arrhythmia in preclinical models?
Does rostafuroxin prevent ouabain-induced electrophysiological derangements and arrhythmia in preclinical models?
Rostafuroxin ameliorates ouabain-induced electrophysiological disturbances and intracellular sodium overload in preclinical models, suggesting potential as a treatment for cardiac glycoside toxicity.
Answers are grounded in this paper and cite their sources.
Does not support clinical use for glycoside toxicity; leaves open translation from avian models to arrhythmia prevention.
Cardiac glycosides (CG) like ouabain exert positive inotropic effects by inhibiting the Na + -K + -ATPase. CGs wide spread use is limited by CGs narrow therapeutic window. Mis- or overdosing with CGs may cause cardiac arrhythmias, resulting from electrolyte disturbances. To study the ethically challenging topic of CG overdosing, we here optimized the in ovo platform to test, if treatment with the selective ouabain antagonist rostafuroxin prevents CG-mediated electrophysiological derangements and arrhythmia by restoring electrolyte homeostasis. We employed incubated chicken eggs (iCEs), a 3R-compliant model, for which we established Electrocardiograms (ECGs). ECGs were recorded under i) baseline conditions, ii) after treatment with ouabain and iii) after co-treatment with rostafuroxin. Underlying mechanisms of ouabain and rostafuroxin effects were studied using blood gas analysis and fluorescence microscopy. Isolated murine and human cardiomyocytes served as an independent model to confirm in ovo results. Ouabain treatment resulted in increased heart rate variability (HRV), transient sinus arrest, and atrio-ventricular dyssynchrony, accompanied by plasma hyperkalemia and cardiomyocyte Na + overload. Co-treatment of ouabain and rostafuroxin led to reduced HRV and ameliorated the frequency and duration of transient sinus arrest, while plasma K + levels remained unchanged. In isolated cardiomyocytes, ouabain treatment induced intracellular Na + overload which was abolished by additional rostafuroxin treatment. Our work demonstrates the in ovo platform and corresponding readouts as a suitable tool to study cardiac electrophysiology in a 3R compliant manner. We found, that rostafuroxin treatment ameliorated ouabain-induced electrophysiological disturbances, suggesting rostafuroxin as a potential therapeutic intervention for ouabain mis- or overdosing.
No takes yet. Share an insight, caveat, or question.
Rees et al. (2026) studied this question. Rostafuroxin co-treatment reduced ouabain-induced heart rate variability and sinus arrest, normalizing cardiomyocyte Na+ overload without changing plasma K+ levels.
Synapse has enriched 10 related papers. Consider them for comparative context: